Neurological Aspects of THC as a Treatment for Generalized Anxiety by Kelly, Khaliah
Lincoln University
Blue Tiger Commons@LincolnU
Show Your Stripes Research and Creative Showcase 2019 Show Your Stripes Research and CreativeShowcase
Apr 11th, 11:45 AM - 12:00 PM
Neurological Aspects of THC as a Treatment for
Generalized Anxiety
Khaliah Kelly
Lincoln University, Jefferson City Missouri, khaliah.kelly062@my.lincolnu.edu
Follow this and additional works at: https://bluetigercommons.lincolnu.edu/showyourstripes
Part of the Biology Commons
This Event is brought to you for free and open access by the Conferences and Events at Blue Tiger Commons@LincolnU. It has been accepted for
inclusion in Show Your Stripes Research and Creative Showcase by an authorized administrator of Blue Tiger Commons@LincolnU. For more
information, please contact MartinD2@lincolnu.edu.




Marijuana/Cannabinoids therapeutic effects on Anxiety 
Khaliah Kelly 





• Endocannabinoid System 
• EndoCannabinoid System overlapping the limbic system of Anxiety 
• Cannabinoid Receptors & Signaling in the Limbic System 
• Drugs targeting cannabinoid receptors to treat Anxiety 
• Summary Points 
• Future Issues & Impact 
• Acknowledgments 
• Literature Cited 
	 	  2
Abstract 
 Currently, 1 in 13 people (264 million people) are diagnosed in the world with 
anxiety disorder. Anxiety is a disorder that causes random or triggered panic attacks 
due to an imbalance of neurotransmitters in the limbic system of the brain. Marijuana 
(Cannabis sativa) contains high levels of delta-9-tetrahydrocannabinol (THC). THC acts 
as a neurotransmitter and is able to attach to molecules called cannabinoid receptors on 
neurons, activate them, which results in changes in mental and physical functions. The 
neural communication network used by THC neurotransmitters is known as the 
endocannabinoid system. The endocannabinoid system and the limbic system are 
interconnected and share the use of cannabinoid receptors. Therefore, THC derived 
medications has a potential to alleviate anxiety symptoms by rebalancing of 
neurotransmitters in the limbic system. 
Introduction 
 Marijuana, also known as Cannabis, contains a psychoactive component called 
delta-9-tetrahydrocannabinol (THC), which essentially causes the “high” effect known 
from consuming or smoking the plant. Marijuana also contains cannabidiol (CBD) which 
has shown some medically beneficial effects on serious neurological disorders and 
more (Zou et al., 2018). C. sativa is tall, long, and with narrow leaves, and provides an 
energizing, stimulating effect, producing a greater amount of THC than CBD. On the 
other hand, C. indica is a short and broad plant with thick, dense leaves, and provides a 
more relaxing, calming effect, producing an equalized ratio between THC than CBD 
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(McPartland, 2017). C. sativa strain is used in the medical industry because of its ratios 
between THC and CBD, which is more ideal to reach more audiences including 
children. The C. sativa strains’ low CBD and high THC content will cause more of an 
effect on the CB1 and CB2 production, which comes primarily from the  THC 
component. Marijuana is trending in the medical world, and recently, research has 
proven that use of cannabinoids might be beneficial on curing and/or alleviating some of 
the most common diseases/disorders, including anxiety. 
 Anxiety is a psychiatric disorder that causes panic and apprehension in response 
to stress. It can be caused by various sources: trauma, genetic inheritance, fear/
phobias, environmental stress, among other things. The disorder effects 18.1% of the 
U.S. population each year, totaling up to more than 40 million people (ADAA). Anxiety 
causes chemical changes in the limbic system, which includes the amygdala, 
hippocampus and the hypothalamus of the brain (Zou et al., 2018). 
 The endocannabinoid system (ECS) is a multi-region complex of several brain 
areas: medial prefrontal complex, amygloid complex, hippocampus, and the dorsal 
periaqueductal gray (Murrough, 2015) and overlaps 2/3 of the limbic regions. Current 
research on the two agonist cannabinoid receptors, CB1 and CB2, are helping to 
understand the role of cannabis on anxiety. 
 In this review, research about the endocannabinoid system, CBR receptors & 
signaling within the central nervous system, the significance of the overlapping systems 
between ECS and anxiety, and how cannabinoids & related medicines are being used 
and examined for anxiety will all be analyzed. 
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The Endocannabinoid System 
 Did you know that everyone has an endocannabinoid system? The ECS is self-
governed and has receptors all over the body, your body even produces a very small 
number of natural cannabinoids. However, when a person consumes THC from 
marijuana in whichever form they prefer, there ends up being excess of cannabinoids in 
the system, disrupting the balance. Cannabinoids don’t only just effect the brain, but 
other regions of the body where the receptors reside. 
 The ECS involves two cannabinoid receptor that cells in the body express called 
CB1 and CB2 (these are agonists), these are found in the immune system and very 
abundant in the central nervous system. The agonists are what really establish the 
connection between cannabis and the body, these agonists initiate a response once its 
combined with a receptor (Zou, 2015). It is possible that anxiety can be alleviated with 
medical marijuana (sativa) use due to how closely related the systems are and the 
interactions and overlap between them. 
Endocannabinoid system overlapping the limbic system of Anxiety 
 The idea of anxiety is linked with fear, and fear is a result of the body responding 
to a possibly dangerous stimulus, to lead the organism to promote survival (Ruehle et 
al., 2011). Therefore, anxiety is natural, although disruptions in the balance of the 
neurotransmitters can cause neurological dysfunctions which the illness anxiety is. 
Anxiety is frequent occurrence of one or more stimuli triggering the exhausting 
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symptoms of anxiety, when it's not of dire need to express these symptoms. Those who 
suffer from anxiety disorder, have an imbalance in the emotional area of the brain of the 
limbic system (Martin et al., 2013). The limbic system contains some of the same areas 
of the brain of the endocannabinoid system, controlling the body’s perception of senses, 
pain, fear, stress, mood and more. The crossover of the two systems in the same brain 
regions play an important role in how the ECS functions in relation in how cannabinoids 
can effect anxiety. Those with anxiety disorder will have decreased inhibitory signaling 
or increased excitatory neurotransmission in the communication between brain cells via 
gamma-amino-butyric acid (GABA - reducing neuronal activity) or glutamate (increasing 
neuronal activity). When activated by CB1Rs, GABA will have anxiogenic response, 
inducing anxiety. On the other hand, glutamate creates an anxiolytic response, reducing 
anxiety. These two neurotransmitters are known in the ECS for possessing cannabinoid 
CB1 receptors in the axon terminals, when activated, CB1 can play its role in inhibiting 
the production of GABA by controlling its release (Laaris et al., 2010), therefore, causing 
a push against the unbalanced neurotransmitters and reducing anxiety’s effects. 
However, just like everything else, CB1R agonists can have pros and cons; too many of 
the receptors can cause anxiogenic effects, and not enough agonists can lead to 
anxiolytic effects (Ruehle et al., 2011). Theses two transmitters do not work together, so 
to regulate anxiety, the focus point is to regulate the both of them equally so that no 
anxiogenic response occurs.  
 Studies was conducted by several research teams to test the conation between 
cannabinoid receptors and the neurotransmitters, there were three main tests used to 
analyze the levels of stress the subject mice: light/dark box test, elevated plus-maze, 
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and Vogel conflict test. After a knockout of CB1R was analyzed, comparing wild type 
mice to mice with the knock out of CBRs, resulted in an anxiogenic response in the 
mice with the knock out. Although, the study resulted in a strong decrease or increase of 
an anxiety response, the absence of the CB1R solely depends on which 
neurotransmitter is more abundant (Ruehle et al., 2011). This study expresses how 
cannabinoid receptors are bimodal when expressing anxiety, because of the 
neurotransmitters they interact with. Even directly injected THC into different areas of 
the brain result in two different dominances of the neurotransmitters. When injected into 
the prefrontal cortex, there is a anxiolytic effect, versus when injected in the basal 
amygdala, theres an anxiogenic response (Ruehle et al., 2011). A possible explanation 
goes along the lines of expression of a dominant neurotransmitter in various areas of 
the limbic system this all connect to how anxiety works in the body, these results may 
vary. Another study conducted by Haller and her team to observe the effects of agonist 
cannabinoids (WIN-55,212) compared to the cannabinoid antagonist (AM-251) in mice 
and wistar rats, they believed that the variations of the antagonist-agonist interactions 
were species related. Which makes sense because some animals can be more fearful 
(increased anxiety) than other animals. For example, smaller, more preyed on animals 
vs larger, predatory animal would have different triggers for anxiety. In the study, the 
team hypothesized that the species’ effects from cannabinoids were sensitive on 
expression of GABA and glutamate on anxiety (Haller et al., 2007). During the control 
period of the experiment, the researchers regulated the mice and rats in a stable lab 
conditions, so that they can become used to it, and already they seen environmental 
factors that could effect the experiment (hierarchy/ social status between the animals), 
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so they separated every subject to focus solely on the behavior, instead of 
environmental factors. They studied several series of experiments, comparing and 
contrasting these effects of higher and lower concentration (0.3 mg/kg and 1 mg/kg) of 
agonists or (1mg) antagonist, light and dark, isolation and combination, and functionality 
of the subjects in the plus maze, the results followed: the antagonist had an anxiogenic 
effect on the mice, closed-arm entries were not effected (P> 0.2), and open-arm entries 
were significantly reduced compared to the control (P<0.003 & P= 0.057); on the other 
hand, rats didn’t respond to the antagonist as the mice, closed-armed entries weren’t 
significantly different (P< 0.5), open-armed entries weren’t significantly different (P<0.7) 
(Haller et al., 2007). In the mice specifically, the results show that the WIN-55,212 
agonist decreased anxiety, but on the other hand, the same agonist created an increase 
in anxiety in the rats. The article compares the activation of cannabinoid receptors in 
several species, and there is a significant different in what species’ CBR1/CBR2 will 
release which neurotransmitter. Fortunately, mice and humans have the same reactions 
when the cannabinoid receptors 1 and 2 are activated. 
Cannabinoid receptors and signaling in the limbic system 
 The receptors of the endocannabinoid system are very much expressed 
throughout the central nervous system with or without the assistance of cannabis. The 
CB1 and CB2 receptors are G-protein-coupled receptors (GCPRs), agonists within the 
endocannabinoid system that are represented across neurological systems, they 
function together to degrade metabolism, cellular uptake, and endocannabinoid 
biosynthesis (Pertwee, 2012). The other endocannabinoids that are produced by the 
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body, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) help activate the CB1 and 
CB2 receptors and begin the up-regulation/ down-regulation of the psychoactive 
neurotransmitter balance in the body (Mouhamed et al., 2018). CB1 differs from CB2 
because it is localized at the presynaptic terminals, hence their function to inhibit 
neurotransmitter release and regulate cytokine release; whilst CB2 receptors 
concentrate in the immune system (Pertwee, 2005). These synapses occur with the 
brain region of the limbic system specifically the amygdala, which is why it’s an 
important location for intertwining the two systems. The amygdala controls fear 
response, expressing as symptoms of anxiety, the synapses here are extremely 
important to the overall expression of GABA and glutamate to determine what actually 
triggers symptoms in which part of the amygdala. As previously mentioned, the 
neurotransmitters GABA and glutamate are expressed to create an influx within the 
nervous system to directly cause anxiogenic or anxiolytic effects on the body. When 
CB1 is activated, it usually leads to inhibition of release of GABA, using the agonist (as 
mentioned previously) WIN-55,212 (Ruehle, et al., 2012), this method can be very 
efficient in the control of anxiogenic effects. However, THC can manifest both anxiolytic 
and anxiogenic characteristics because when its bound to CB1 receptors, release of 
both GABA and glutamate compounds (Pertwee, 2005), so it is definitely possible for 
marijuana to cause anxiety or increase its symptoms. Although, if properly regulated by 
dosage, and even singling out THC components, it is possible to correct the imbalance 
and focus on releasing only GABA or only glutamate to properly treat one with anxiety, 
but only if its known which neurotransmitter is causing the imbalance. The process of 
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targeting requires more research for progress on using THC neurological aspect for 
treatment of anxiety.   
Drugs targeting cannabinoid receptors to treat anxiety 
 As the states of the United States are slowly legalizing the use of medicinal 
marijuana, the government has set very strict guidelines and requirements in the 
lengthy process from the specific bud to the patient. The most complicated part is 
educating the physicians on proper criteria on how to prescribe the doses. It is 
recommended to start low to determine the level of euphoria that the patient 
experiences to figure out the amount that is best for the patient to acquire and to avoid 
too high of a dose that can impair cognition of the patient (Murrough et al., 2015). 
Calcium is a key factor in the middle of the these processes, when AEA, 2-AG, or THC 
bind with CB1 in the presynaptic terminal, it regulates the amount of calcium then 
decreases the release of neurotransmitters to travel to the post synaptic terminal. 
Interferences in this process can lead to many different types of reactions in the body, 
which is not ideal, therefore controlling this regulation is what the drugs are needed to 
do. As we know, psychological disorders are usually caused by disfunction or certain 
imbalances in the neurotransmitters produced in the brain, here is when the 
endocannabinoid system can come into play. The relation between two systems have 
been thoroughly researched, and in some cases, there will be up regulation in the 
endocannabinoid system that causes symptoms of a disorder/disease in which 
antagonists can aid in down regulation in  the neurological balance (Pertwee, 2005), 
essentially rebalancing the transmitters and stopping symptoms. Pharmacologists will 
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have to identify specific receptors involved and location of the imbalances to then know 
what drug and its abundance can solve the issue. In the case of anxiety, drugs already 
established target serotonin and GABA in the body to regulate symptoms such as: 
headache pains, insomnia, diarrhea/nausea, appetite decrease, fatigue and cognition 
issues (Mouhamed et al., 2018). Big “pharma” has worked on synthesizing the creating 
a version of THC that can be easily administered and can avoid the other effects of 
marijuana without actually using marijuana, hence there were be neurological effects 
without the side effects. One of the top choice of treatments for anxiety already in place 
are benzodiazepines, which enhance the effects of GABA, leading to calming the 
excited signaling of the neuronal synapses overall (slowing down the release of more 
neurotransmitters) (Griffin, et al., 2013), which can be used synergistically with other 
possible treatments for a strong effect on rebalancing the neurotransmitters.  
Conclusion 
In conclusion, GABA and glutamate are the key components to bridging the gap 
between the endocannabinoid system and the limbic system. The secret to balancing 
the neurotransmitters caused by anxiety lies within the mystery of how the receptors 
release neurotransmitters, which ones and how much. Once that has been discovered, 
scientists can pin point the stimulating factor from marijuana in the THC molecules to 
regulate the imbalance and virtually solving the chemical issue with anxiety patient. 
Therefore, marijuana derived treatments can help alleviate symptoms of anxiety, 
although there is much more research needed to done to achieve that goal. There are 
many people in the world suffering from anxiety, and the numbers are increasing. 
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Something needs to be done to lower the stats on this disorder, because it has potential 
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